Editorial comment

摘要

The authors present data showing that a PSA slope <2 pg/mL/ mo obtained using a new ultrasensitive assay (NADiA ProsVue) predicts a decreased risk of prostate cancer recurrence after RP. Disease recurrence was defined very strictly as positive biopsy findings, radiographic evidence of disease, or death from prostate cancer. Biochemical failure alone was not considered clinical disease recurrence. A biorepository was used that collected serum samples from patients treated from 1990 to 2001 at Duke University, Eastern Virginia Medical School, Memorial Sloan-Kettering Cancer Center, and the University of Washington. Clinical data were extracted from the medical records. A total of 304 patients were identified whose initial PSA level was <0.1 ng/mL after RP. The ProsVue results were calculated for each patient using 3 samples from multiple measurement points after prostatectomy. The follow up duration was <=17.6 years, and the median follow' up was >10 years.